99548-52-4

Basic information

• Product Name: 2-(5-bromo-2-nitrophenylamino)propionic acid
• Synonyms: 2-(5-bromo-2-nitrophenylamino)propionic acid
• CAS NO: 99548-52-4
• Molecular Weight: 289.085
• Mol File: 99548-52-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(5-bromo-2-nitrophenylamino)propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-bromo-2-nitrophenylamino)propionic acid(99548-52-4)
• EPA Substance Registry System: 2-(5-bromo-2-nitrophenylamino)propionic acid(99548-52-4)

Safety Data

• Hazardous Substances Data: 99548-52-4(Hazardous Substances Data)

Usage

General Description

2-(5-bromo-2-nitrophenylamino)propionic acid is a chemical compound that contains a 2-nitrophenylamino group and a propionic acid moiety. 2-(5-bromo-2-nitrophenylamino)propionic acid is commonly used as a reagent in the synthesis of various pharmaceuticals and organic compounds. Its chemical structure consists of a propionic acid backbone with a 5-bromo-2-nitrophenylamino group attached to the alpha carbon. The presence of both the nitro and bromo groups makes this compound useful in various chemical reactions, including nucleophilic substitutions and coupling reactions. It is often utilized as a building block in the preparation of bioactive molecules and can exhibit biological activity in certain applications.

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 302-72-7 rac-Ala-OH 
• 56-41-7 L-alanin 
• 51686-78-3 2,4-dibromonitrobenzene 

Downstream Products

• 24463-25-0 6-bromo-3-methyl-3,4-dihydro-1H-quinoxalin-2-one 
• 1417408-91-3 7-bromo-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1427029-40-0 1-(2-chlorophenyl)-7-ethynyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1427029-41-1 1-(2-chlorophenyl)-4-methyl-7-trimethylsilanylethynyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1427029-12-6 2-(5-bromo-2-nitrophenylamino)propionic acid methyl ester 

Relevant articles and documents

TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

Combination therapies using benzimidazolones

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R6are independently selected from H or optionally substituted C1to C6alkyl, C2to C6alkenyl, C2to C6alkynyl, C3to C8cycloalkyl, substituted C3to C8cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4and R5to from a 5 to 7 membered ring; R1is selected from H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, substituted alkynyl, —COH, or optionally substituted —CO(C1to C3alkyl), —CO(aryl), —CO(C1to C3alkoxy), or —CO(C1to C3aminoalkyl) groups; R2is selected from H, halogen, CN, NO2, or optionally substituted C1to C6alkyl C1to C6alkoxy, or C1to C6aminoalkyl groups; R3is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromnatic ring containing 1 or 2 substituents; or a pharmaceutically acceptable salt thereof, in combination with a progestational agent, an estrogen, or both or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. These combinations may also be used to in methods of contraception, to stimulate food intake or for minimization of side effects or cyclic menstrual bleeding.